RDIF brings together the best Russian
and international technologies in the fight
against COVID-19
Production of the first registered
COVID-19 vaccine in the world

The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.

Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long lasting immunity.

The efficacy of the Sputnik V vaccine is confirmed at 91.6  % based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two dose vaccine). The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.

The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.

After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund and Gamaleya Institute on November 23, 2020 offered AstraZeneca to use one of the two components (human adenoviral vectors) of the Sputnik V vaccine in AstraZeneca’s clinical trials.

AstraZeneca accepted RDIF’s proposal and began clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.

For more information visit www.sputnikvaccine.com and follow Sputnik V on social networks.

Production of antiviral drugs

RDIF and the ChemRar Group have launched the production of Avifavir - the first drug registered in Russia that has demonstrated effectiveness against COVID-19 in clinical trials.

Avifavir is one of the two registered COVID-19 drugs in the world and the first Favipiravir-based drug in the world approved for treatment of COVID-19.

Production of diagnostic tests for the detection of coronavirus

Jointly with Japan’s K.K. Mirai Genomics, RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG - Evotech-Mirai Genomics, which is one of the world’s most accurate and fastest systems for the detection of coronavirus. Results are achieved in just 30 minutes. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund.

Diagnosis and detection of pneumonia

RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus, using CT scans combined with the Russian- UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group.

Production of a drug for coronavirus therapy based on blood plasma

RDIF and Rostec partner announced a partnership with Nacimbio (part of the State Corporation Rostec) to carry out a joint project for the production of a drug for coronavirus therapy based on blood plasma. One of Nacimbio’s enterprises has developed a universal technology for the production of human immunoglobulins for intravenous administration. The BioGam drug produced using this technology has successfully passed the first phase of clinical trials. The partnership involves the production of an immunoglobulin preparation containing antibodies to the SARS CoV-2 coronavirus.

RDIF announces RDIF. Healthcare

RDIF. Healthcare – an investment channel with a strategic focus on the implementation of projects in the healthcare sector. RDIF has been actively involved in fighting COVID-19 through working on healthcare projects.

Before the pandemic, a number of healthcare projects have been launched as part of the fund’s investment strategy aimed at improving general quality of life. Further development of healthcare investment is the next stage in the process.